Treatment pattern in patients with idiopathic membranous nephropathy-practices in Sweden at the start of the millennium

Artikel i vetenskaplig tidskrift, refereegranskad
Författare
Jennie Lönnbro-Widgren | Institutionen för medicin
Johan Mölne | Institutionen för biomedicin, avdelningen för patologi
Börje Haraldsson | Institutionen för medicin
Jenny Nyström | Institutionen för neurovetenskap och fysiologi
Publikationsår
2016
Publicerad i
Clinical Kidney Journal, 9 (2), 227-233
Sammanfattning
Background Idiopathic membranous nephropathy (MN) is one of the leading causes of nephrotic syndrome in adults and may result in end-stage renal disease (ESRD). In this retrospective study, we describe the outcomes and treatment patterns of patients with idiopathic MN in six nephrology clinics in the western part of Sweden. Methods Seventy-three consecutive patients with biopsy-proven MN in the years 2000-12 were classified as idiopathic, i.e. secondary forms were excluded. The patients were followed retrospectively for a mean period of 83 months and clinical data were collected through the medical files. Results A high proportion (88%) of the patients received supportive treatment with angiotensin-converting enzyme inhibition, angiotensin receptor blockade and/or statins. At the end of follow-up, 43 patients were in complete remission, 12 in partial remission, 10 patients had developed ESRD and 8 patients had on-going proteinuria. Fifty-one per cent of the patients received immunosuppressive therapy and the choice of therapy varied between and within the clinics. There was a tendency to initiate specific treatment at an early point instead of awaiting a possible spontaneous remission (21% of the patients), and non-recommended therapy such as corticosteroids only was used in a high proportion of these cases (47%). Conclusions Even though the treatment recommendations in idiopathic MN have not changed the last decade, the question of whom and when to treat seems to lead to uncertainty. Recent studies have presented promising results supporting the PLA2R antibody the predictive marker needed for this patient group. The diverse treatment approach presented in this study might have resulted in a worse outcome than expected. Hopefully, unnecessary exposure to immunosuppressive therapy or delayed treatment can be avoided through better support, education and treatment forums, and thus result in an improved outcome. © The Author 2016. Published by Oxford University Press on behalf of ERA-EDTA.
ISSN
2048-8505
Ämnesord
  • Medicin och hälsovetenskap | Klinisk medicin | Neurologi
  • Medicin och hälsovetenskap | Klinisk medicin | Autoimmunitet och inflammation
  • Medicin och hälsovetenskap | Klinisk medicin | Gastroenterologi och hepatologi
  • Medicin och hälsovetenskap | Klinisk medicin | Njurmedicin
Nyckelord
end-stage renal disease, glomerulonephritis, membranous nephropathy, proteinuria
Språk
Engelska
Publikations-ID
243315
Identifikatorer